Global Health Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
MEDANTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.4 pts more than Nifty Midcap 150 and 6.8 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Global Health Limited (Medanta) announced its Q1 FY26 results for the quarter ended June 30, 2025. Standalone revenue from operations grew to ₹8,821.56 million from ₹7,578.62 million (restated) in Q1 FY25, a rise of about 16%. Standalone profit after tax jumped to ₹1,519.64 million from ₹1,085.51 million, up roughly 40%, with EPS at ₹5.66 versus ₹4.04. Consolidated revenue rose to ₹10,308.37 million and consolidated PAT climbed to ₹1,589.82 million from ₹1,062.64 million, an increase of nearly 50%. The board also declared a final dividend of ₹0.50 per share for FY25 with record date August 22, 2025, and approved the re-appointment of Dr. Naresh Trehan as CMD for another 5 years, along with two independent directors. Additionally, comparative figures have been restated due to the merger of wholly-owned subsidiary Medanta Holdings Private Limited, which became effective from April 1, 2024.
Strong PAT growth driven by both higher revenues and operational leverage should be viewed positively by shareholders, though the restated comparable numbers warrant careful year-on-year comparison. The final dividend, leadership continuity, and a new hospital expansion in Guwahati signal stable growth momentum, with a likely short-term positive sentiment on the stock.